PresseBox
Press release BoxID: 109207 (Evotec AG)
  • Evotec AG
  • Manfred Eigen Campus, Essener Bogen 7
  • 22419 Hamburg
  • http://www.evotec.com
  • Contact person
  • Anne Hennecke
  • +49 (40) 56081-286

Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201

(PresseBox) (Hamburg , ) .

- Both co-primary endpoints, Wake After Sleep Onset and Total Sleep Time, and key secondary endpoints, including Latency to Persistent Sleep, were met at both doses
- Evotec to host a conference call at 4pm CET (3pm UK time, 10am EST) today

Evotec AG (Frankfurt Stock Exchange: EVT) announced today positive top-line results from its first phase II clinical trial of EVT 201 in patients with chronic primary insomnia. EVT 201 is a partial positive allosteric modulator (pPAM) of the GABAA receptor complex. The double-blinded, placebo controlled cross-over study design of two doses of EVT 201 (1.5mg and 2.5mg) in 67 patients was conducted in sleep labs in the US using objective polysomnography. The pre-specified intention-to-treat analysis of the study showed statistically highly significant improvements between both doses of EVT 201 and placebo in both of the co-primary endpoints of Total Sleep Time (TST) (p